Ocuphire Pharma
primary of subjects study eye returning to at min | Ocuphire Pharma
Company
Deck Type
Deck date
March 2021
Slide
11 of 29
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Results
March 2022
mean pupil diameter over time by eye color | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time by mydriatic agents | Ocuphire Pharma
Results
March 2022
mean pupil diameter over time | Ocuphire Pharma
Results
March 2022
comparison of one drop fellow eye with two drops study eye | Ocuphire Pharma
Related slides by other companies
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
Adagio Therapeutics
Results
November 2023
the canopy phase clinical trial of is designed to rapidly generate clinical data for a potential | Adagio Therapeutics
ATAI
Investor Presentation
February 2023
phase proof of concept trial design all subjects tid tid placebo trial status recruitment ongoing results anticipated randomized week study of and in patients with | ATAI
ATAI
Investor Presentation
January 2023
phase proof of concept trial design all subjects tid tid placebo trial status recruitment ongoing results anticipated randomized week study of and in patients with | ATAI
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights